Cardiac Amyloidosis

With the first drug treatments for cardiac amyloidosis recently entering the market, there has been an explosion of interest to diagnose and care for these patients. It is considered a rare disease, but many experts now say it is actually just be under diagnosed. The disease is caused by protein misfolding. Normally soluble proteins in the bloodstream become insoluble and deposit abnormally in the tissues and organs throughout the body. There are three main kinds of amyloid that affect the heart, light chain amyloid (AL) and two types of transthyretin amyloid (ATTR or TTR). The first type of ATTR is hereditary, or familial amyloid, and the second is wild type, or age-related TTR amyloid. Nuclear imaging, echocardiography, CT and MRI all play roles in diagnosing amyloid and in determining the subtype, which is required for targeted treatment. 

cardiac amyloidosis on bone scan

Cardiac amyloidosis becoming less rare thanks to nuclear medicine studies

A new study in the Journal of Nuclear Medicine offers insight into how the condition affects the general population, as well as how radiologists can help in the cardiac amyloidosis diagnostic journey.

Thumbnail

AI specialists ink deal with Pfizer to target cardiac amyloidosis

Cardiac amyloidosis can be especially challenging to identify and diagnose, making it a perfect target for advanced AI models.

Late-breaking cardiovascular study presentation at AHA 2022. #AHA22

VIDEO: Key takeaways from AHA 2022

Manesh R. Patel, MD, chair of AHA Scientific Sessions program, explains what he saw as the top takeaways from AHA 2022.

Thumbnail

Amyloidosis patients can safely undergo TAVR

Researchers focused on 30-day outcomes, sharing their findings in the American Journal of Cardiology.

DOACs outperform VKAs among cardiac amyloidosis patients with HF, AFib

Outcomes from patients prescribed apixaban, rivaroxaban or dabigatran were compared with outcomes from patients given warfarin. 

Attralus completes financing to validate pan-amyloid nuclear imaging agent

Biopharmaceutical firm Attralus has completed a $25 million Series A financing designed to further validate its AT-01 pan-amyloid radiotracer for PET/CT.

Thumbnail

Specialists share experience prescribing a historically expensive cardiovascular medication

Tafamidis received FDA approval in May 2019 for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). It has a list price of $225,000 per year.

Thumbnail

Heart transplants provide value for patients with AL, ATTR cardiac amyloidosis

With the disease becoming more and more common in the United States, researchers have been hard at work determining the best possible treatment options.